The ArteraAI Prostate Test (mHSPC) is the first externally developed digital pathology algorithm being made clinically available through the Tempus ecosystem. This AI-powered test assesses a patient's ...

In a recent interview with CURE, Dr. Kai Tsao discussed treatment advancements for patients with prostate cancer. In a recent interview with CURE, Dr. Kai Tsao broke down current treatment ...

Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...

About 1 in 8 men will be diagnosed with prostate cancer in their lifetime The average age at diagnosis is 67 Less than 1% of the 3.5 million men living with prostate cancer are expected to die from it ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly. Diagnosis involves the TNM system, Gleason score, PSA tests, and imaging to ...

Patented Algorithm Designed to Help Identify Otherwise Dangerous Prostate Tumors Earlier Using Repeat Blood Test Results Licensing Agreement Expands 20/20 BioLabs’ AI-Enabled Multi-Cancer Early ...

Prostate cancer is one of the most common cancers diagnosed in men. Although it is the second-leading cause of cancer-related deaths for men in the U.S., it is also highly treatable, especially when ...

Prostate cancer is the most common cancer among men after skin cancer. Age is a significant risk factor for prostate cancer. Family history and genetic factors play a significant role in prostate ...